Steele Clarke Smith III is a pioneering healthcare innovator best known for leading the development of the first standardized cannabinoid tablet formulated to meet FDA‑level pharmaceutical standards. Through his work with C3 International, Inc., he helped establish a pharmaceutical‑grade foundation for cannabinoid therapeutics—bringing precision dosing, safety and clinical reliability to a space previously dominated by inconsistent products.

Driven by a mission to elevate patient care, Steele continues to champion medical solutions that merge scientific rigor with compassionate innovation, setting new benchmarks for how cannabinoid‑based therapies can be delivered to doctors and patients worldwide.